These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 9309147

  • 21. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V.
    Cancer Res; 1995 Aug 15; 55(16):3569-75. PubMed ID: 7627966
    [Abstract] [Full Text] [Related]

  • 22. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB, Oliff A.
    Annu Rev Pharmacol Toxicol; 1997 Aug 15; 37():143-66. PubMed ID: 9131250
    [Abstract] [Full Text] [Related]

  • 23. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A.
    Cancer Res; 1998 Mar 15; 58(6):1253-9. PubMed ID: 9515813
    [Abstract] [Full Text] [Related]

  • 24. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
    Khan SG, Dummer R, Siddiqui J, Bickers DR, Agarwal R, Mukhtar H.
    Biochem Biophys Res Commun; 1996 Mar 27; 220(3):795-801. PubMed ID: 8607844
    [Abstract] [Full Text] [Related]

  • 25. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 27; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 26. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ, Ciccarone TM, MacTough SC, Shaw AW, Buser CA, Ellis-Hutchings M, Fernandes C, Hamilton KA, Huber HE, Kohl NE, Lobell RB, Robinson RG, Tsou NN, Walsh ES, Graham SL, Beese LS, Taylor JS.
    J Med Chem; 2003 Jul 03; 46(14):2973-84. PubMed ID: 12825937
    [Abstract] [Full Text] [Related]

  • 27. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC, Watkins JD, Ferguson SB, Foley LH, Georgopapadakou NH.
    Biochem Biophys Res Commun; 1995 Dec 26; 217(3):728-32. PubMed ID: 8554591
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
    Terry KL, Casey PJ, Beese LS.
    Biochemistry; 2006 Aug 15; 45(32):9746-55. PubMed ID: 16893176
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG.
    Cancer Res; 1996 Apr 15; 56(8):1727-30. PubMed ID: 8620483
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Inactivation of farnesyltransferase and geranylgeranyltransferase I by caspase-3: cleavage of the common alpha subunit during apoptosis.
    Kim KW, Chung HH, Chung CW, Kim IK, Miura M, Wang S, Zhu H, Moon KD, Rha GB, Park JH, Jo DG, Woo HN, Song YH, Kim BJ, Yuan J, Jung YK.
    Oncogene; 2001 Jan 18; 20(3):358-66. PubMed ID: 11313965
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 38. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, Kamei T, Nishimura S, Tomimoto K.
    Mol Pharmacol; 1998 Jul 05; 54(1):1-7. PubMed ID: 9658183
    [Abstract] [Full Text] [Related]

  • 39. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
    James GL, Goldstein JL, Brown MS.
    J Biol Chem; 1995 Mar 17; 270(11):6221-6. PubMed ID: 7890759
    [Abstract] [Full Text] [Related]

  • 40. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W, Lebowitz PF, Prendergast GC.
    Cancer Res; 1999 May 01; 59(9):2059-63. PubMed ID: 10232587
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.